Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients
Jianzhou Chen, Antonin Lévy, Ai-Ling Tian, Xuehan Huang, Guoxin Cai, Marine Fidelle, Conrad Rauber, Pierre Ly, Eugénie Pizzato, Lisa Sitterlé, Gianmarco Piccinno, Peng Liu, Sylvère Durand, Misha Mao, Liwei Zhao, Valerio Iebba, Hannah Felchle, Anne-Laure Mallard de La Varende, Julius C. Fischer, Simon Thomas, Tim F. Greten, Jennifer Jones, Cecilia Monge, Sandra Demaria, Silvia C. Formenti, Lorenzo Belluomini, V. Dionisi, Christophe Massard, Pierre‐Yves Blanchard, Charlotte Robert, Clément Quevrin, Eloise Lopes, Céline Clémenson, Michele Mondini, Lydia Meziani, Yizhou Zhan, Chengbing Zeng, Qingxin Cai, Daphné Morel, Roger Sun, Pierre-Antoine Laurent, Monica Mangoni, Vanessa Di Cataldo, C. Arilli, Maike Trommer, Simone Wegen, Sebastian Neppl, Rachel P. Riechelmann, Marcos Pedro Guedes Camandaroba, Elson Santos Neto, Pierre‐Edouard Fournier, Nicola Segata, Peter Holíček, Lorenzo Galluzzi, Aitziber Buqué, Carolina Alves Costa Silva, Lisa Derosa, Guido Guido Kroemer, Chuangzhen Chen, Laurence Zitvogel, Éric Deutsch (2025). Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients. , 43(3), DOI: https://doi.org/10.1016/j.ccell.2025.02.010.
Article319 days agoA first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors
Christophe Massard, Jean‐Charles Soria, Alan Anthoney, Alicia M Proctor, Angela Scaburri, M. A. Pacciarini, B. Laffranchi, Cinzia Pellizzoni, Guido Guido Kroemer, Jean‐Pierre Armand, Rastilav Balheda, Christopher Twelves (2011). A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors. , 10(6), DOI: https://doi.org/10.4161/cc.10.6.15075.
Article319 days agohTERT: a novel endogenous inhibitor of the mitochondrial cell death pathway
Christophe Massard, Yaël Zermati, A-L Pauleau, Nathanaël Larochette, David Métivier, Laure Sabatier, Guido Guido Kroemer, J.C. Soria (2006). hTERT: a novel endogenous inhibitor of the mitochondrial cell death pathway. , 25(33), DOI: https://doi.org/10.1038/sj.onc.1209487.
Article319 days agoFinal Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial
Johann S. de Bono, He Meng, Zhen Shi, Małgorzata Nowicka, Sergio Bracarda, Cora N. Sternberg, Kim N., David Olmos, Shahneen Sandhu, Christophe Massard, Nobuaki Matsubara, Geng Chen, Nives Selak Bienz, Daniel Canter, Matthew Wongchenko, Christopher J. Sweeney (2025). Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial. , DOI: https://doi.org/10.1016/j.eururo.2024.12.015.
Article309 days agoSafety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer
Nobuaki Matsubara, Johann S. de Bono, Christopher Sweeney, Kim N., David Olmos, Shahneen Sandhu, Christophe Massard, Josep Garcia, Geng Chen, Adam Harris, Fanny Schenkel, Rucha Sane, Healther Hinton, Sergio Bracarda, Cora N. Sternberg (2023). Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer. , 21(2), DOI: https://doi.org/10.1016/j.clgc.2023.01.001.
Article309 days ago